I didn't just stop scooping poop with the Litter Robot 4, it kept my cats healthy — here's how
While I can't tell you enough how awesome it is to have this robotic litter box in my home to do the dirty duty of picking up my cats' poops, there's actually another feature about the Litter Robot 4 that I find equally as valuable. I honestly didn't think much of it the first few months, but its ability to monitor and track the weight of my cats has proven to be invaluable.
In fact, it helped me to uncover a medical condition that was left undiagnosed for months with my cat Andy — and for that, I couldn't be grateful.
Save yourself from constantly having to clean up after your cats with Whisker's Litter Robot 4. This robotic litter box not only cleans up after them, but its smart features allow you to track how frequently they use it and how much they weigh. With an assortment of accessories, it accommodates just about every feline no matter the breed, age, or size.
As much as it takes the hassle away from cleaning up after my cats, the Litter Robot 4 has sensors that allow it to weigh them each time. At first, I didn't think much of this until one day I noticed my cat Andy started to feel a bit boney, especially around his back. He's been a hefty little feline, but I only realized his sudden weight change after I picked up my other cat Vader — who's even chonkier.
For years taking Andy to the veterinarian, his weight would range from 10 to 12 pounds — so you can imagine my surprise to see it under 10 pounds through the Whisker app. What was even more of a shock was that his weight was trending downwards for the last couple of months, so we immediately took him to the vet.
Our veterinarian eventually diagnosed him with IBD (Inflammatory Bowel Disease), so he was put on different medication and a new diet to see if he could pack on the pounds again.
Long story short, it's been a struggle with his weight reaching as low as 8 pounds — but through the different remedies and medication, he's been on the upward trend the last 6 months.
Get instant access to breaking news, the hottest reviews, great deals and helpful tips.
Through it all, the Litter Robot 4 allowed me to monitor any big changes week by week. This feature came in hand because we were able to see how well he responded to different remedies. Best of all, it gave me accurate results because it weighs him each time he uses it.
Since he's older now, I also like how I can tailor my Litter Robot 4 to meet my exact needs. Most other robotic litter boxes my cats have tested are raised, so oftentimes they fly out of the litter box when they're done — splattering messy pieces of litter everywhere.
With the Litter Robot 4, I have a fence installed at the opening to lessen this. I also like how there's a ramp that can help older cats with mobility issues to enter and leave it. Here's hoping for another 2.5 years of faithful service.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 days ago
- Yahoo
RSV symptoms as 'serious virus' coming to UK after Australia surge
NHS experts have urged people who are eligible for a vaccine against respiratory syncytial virus (RSV) to take it up after cases surged in Australia. Australia saw a record number of RSV cases last year, and NHS officials have suggested that the Australian winter often provides a good indication of how viruses will spread in England. Since the start of 2025, the virus has been progressively spreading, with nearly half of reported cases occurring in children under five years old. Kate Brintworth, chief midwifery officer for NHS England, said: "Getting vaccinated while pregnant is the best way to protect your baby from the moment they are born, and now is the time for mums to act, to make sure their babies are protected ahead of their first few months this winter, when there tends to be more bugs circulating." READ MORE: Walker spots giant 'alien' jellyfish washed up on beach READ MORE: Warning over serious virus affecting newborns after surge in cases Dr Andy Whittamore, GP and clinical lead at Asthma + Lung UK, who has pointed out the key symptoms to watch out for and shared some strategies to help protect yourself and your family. What is RSV? He said: "Respiratory syncytial virus is a virus that causes symptoms very similar to the common cold, most of us get it at some point and don't even know that we've had it." According to Asthma + Lung UK, up to 9 in 10 children will contract RSV before they turn two years old and around 175,000 people over the age of 65 visit their GP about RSV each year. How does it spread? Dr Whittamore said: "Like most respiratory viruses, RSV spreads by people coughing and sneezing droplets from their own respiratory tract and it is spread to other people that way, It is often spread and caught in the air, by contact or if it ends up on surfaces." While RSV can circulate all year round, it typically peaks during the colder months. He said: "We see a major peak in cases in the NHS between October and February, particularly in December/January time." What are the most common symptoms? "As a GP, I see a lot of people with respiratory viruses and you can't really tell whether it's flu, Covid, RSV or the common cold," Dr Whittamore says. "Common symptoms are a runny nose, blocked nose, sneezing, coughing, feeling tired etc. People might also have a fever with it and if it's affecting their respiratory system itself, they might experience breathless or wheezing as well." A high temperature is also another key sign to look out for, according to the NHS website. Dr Whittamore said: "For most people, these symptoms tend to last no more than a week to 10 days." Can it lead to any serious complications? RSV can lead to some serious complications such as pneumonia or bronchiolitis for high-risk groups such as babies, young children and older people. Dr Whittamore said: "What we see with RSV, especially in younger children under the age of two, is that it can cause bronchiolitis, which causes quite dramatic breathing effects which can quite often put people in hospital. "We are also seeing that RSV is having a big impact on people over 75. We know that in that age group, the virus is more likely to cause them problems with their breathing and could go on and cause pneumonia and is likely to increase their chances of going to hospital." The NHS website also states that individuals with weakened immune systems, or long-term lung or heart conditions, and those who smoke tobacco are also at risk. A more serious infection (such as pneumonia or bronchiolitis) may cause a cough that gets worse, shortness of breath, noisy breathing (wheezing), faster breathing or long gaps between breaths, difficulty feeding in babies or loss of appetite, and confusion in older adults, according to the NHS website. How is it treated? RSV often improves on its own in one or two weeks, so you can usually manage it at home. Dr Whittamore said: "One important thing to do is to keep well hydrated, people with RSV should be pushing their fluids, resting more, taking paracetamol and can usually monitor themselves. However, if you are worried about yourself or your child, then seek advice from your GP or call 111." Can it be prevented? There are some measures you can take to reduce your chances of contracting RSV or spreading it to anyone else. Dr Whittamore said: "Make sure that when you are blowing your nose or sneezing that you use a tissue and throw it away, also, remember to wash your hands and clean surfaces regularly." The GP emphasises that the most crucial way to prevent people from falling ill with RSV is to ensure you receive the RSV vaccination if you are eligible for it. The RSV jab is recommended if you're expecting (from 28 weeks of pregnancy) – to help safeguard your baby for the first few months after they're born – or if you're aged between 75 and 79. Fresh research from the UK Health Security Agency (UKHSA) has revealed the RSV vaccine is around 82% effective in preventing older people being hospitalised with an RSV infection. "Most GP practices are contacting people and inviting them in, but if somebody thinks they're eligible and haven't been contacted they should contact their GP surgery and see if they can get it booked in," recommends Dr Whittamore.
Yahoo
31-07-2025
- Yahoo
Irritable Bowel Syndrome and Inflammatory Bowel Disease Therapeutics Market Report 2025: Global Trends, Revenue, and Market Dynamics
The global IBS and IBD therapeutics market is set to grow from $33.3 billion in 2025 to $52.6 billion by 2030, at a 9.6% CAGR. The report analyzes market trends, key players, and regional impact, offering insights into drug classes and business strategies of industry leaders like AbbVie and Amgen. Irritable Bowel Syndrome and Inflammatory Bowel Disease Therapeutics Market Dublin, July 31, 2025 (GLOBE NEWSWIRE) -- The "Irritable Bowel Syndrome and Inflammatory Bowel Disease Therapeutics Market" report has been added to global market for irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD) therapeutics is expected to grow from $33.3 billion in 2025 and is projected to reach $52.6 billion by the end of 2030, at a compound annual growth rate (CAGR) of 9.6% during the forecast period of 2025 to and IBD are types of gastrointestinal diseases. The pathophysiology of both diseases is unknown and is believed to be influenced by environmental factors, ethnicity, dietary habits and genetic predisposition. Due to varied symptoms, patients must use multiple therapeutics simultaneously. Therapeutics aim to improve patients' quality of life and achieve clinical remission for the longest period key businesses in the IBS therapeutics market include Ironwood Pharmaceuticals, AstraZeneca, AbbVie, Abbott and Allergan. In the IBD therapeutics market, corporations include AbbVie, Johnson & Johnson Services Inc., Amgen and Biogen. Start-up companies are increasingly entering the IBS and IBD therapeutics market with novel pipeline candidates. Global pharmaceutical companies, such as AbbVie and Amgen, are focused on label expansion studies and licensing collaborations with small businesses to develop and market products. Report ScopeThe report provides an overview of the global irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD) therapeutics market and analyzes market trends. It includes global revenue ($ million) for the base year 2024, estimated data for 2025 and forecast data from 2026 through 2030. The market is segmented into irritable bowel syndrome and inflammatory bowel disease based on disease type. The IBS therapeutics segment is further segmented based on symptom type and drug class. The IBD therapeutics segment is further segmented based on type and drug class. The report also focuses on regional market segmentation. The regions covered in this study include North America, Europe, Asia-Pacific, South America and the Middle East and Africa (MEA), focusing on significant countries in these regions. The report includes an analysis of the competitive landscape, which provides the ranking and share of key businesses in the global IBS and IBD therapeutics market. A dedicated section of company profiles providing details about leading market enterprises is also report includes: 142 data tables and 54 additional tables Analysis of the global market for irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD) therapeutics Analyses of global market trends, with historic revenue data from 2022 to 2024, estimates for 2025, and projected CAGRs through 2030 Estimates of the market's size and revenue prospects, along with a corresponding market share analysis by symptom type, drug class, type, and region Facts and figures pertaining to market dynamics, technological advances, regulations and the impact of macroeconomic factors Insights derived from Porter's Five Forces model, as well as global supply chain analysis Patent analysis, featuring key granted and published patents Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, as well as the ESG risk ratings and practices of leading companies Analysis of the industry structure, including companies' market shares and rankings, strategic alliances, M&A activity and a venture funding outlook Profiles of the leading companies, including AbbVie Inc., Johnson & Johnson Services Inc., Ironwood Pharmaceuticals, Takeda Pharmaceuticals, and Amgen Inc. Key Attributes: Report Attribute Details No. of Pages 155 Forecast Period 2025 - 2030 Estimated Market Value (USD) in 2025 $33.3 Billion Forecasted Market Value (USD) by 2030 $52.6 Billion Compound Annual Growth Rate 9.6% Regions Covered Global Key Topics Covered: Chapter 1 Executive Summary Chapter 2 Market Overview Inflammatory Bowel Disease Irritable Bowel Syndrome Porter's Five Forces Analysis in the IBS and IBD Therapeutics Market Impact of U.S. Tariffs Macroeconomic Factor Analysis Population Demographics and Aging Populations Government Policies on Drug Prices Chapter 3 Market Dynamics Market Drivers Rising Prevalence of Gastrointestinal Disorders Increasing Entry of Biologics and Biosimilars Market Restraints Side Effects and Ceiling Impact of Biologics Overlap with Other Gi Disorders Use of Alternative Treatment Approaches Market Opportunities Self-Administered Drugs Personalized Therapies Chapter 4 Regulatory Landscape Regulatory Aspects of IBS and IBD Therapeutics The U.S. European Union Asia-Pacific Chapter 5 Emerging Technologies and Pipeline Analysis Key Takeaways Emerging Technologies Novel Target-based Small-Molecule Drugs Microbiome-based Therapeutics Advanced Combination Treatments AI for Drug Discovery Pipeline Analysis Chapter 6 Market Segmentation Analysis Market Analysis by Disease Irritable Bowel Syndrome Inflammatory Bowel Disease Market Analysis by Drug Class Irritable Bowel Syndrome Inflammatory Bowel Disease Market Analysis by Region North America Europe Asia-Pacific South America Middle East and Africa Chapter 7 Competitive Intelligence Key Takeaways Industry Structure Company Share Analysis of the IBD Therapeutics Market Competitive Share Analysis of the IBS Therapeutics Market Strategic Analysis Chapter 8 Sustainability in the IBS and IBD Market: An ESG Perspective Introduction to ESG ESG Risk Ratings Company Profiles Abbvie Inc. Amgen Inc. Astrazeneca Bayer AG Biogen Bristol-Myers Squibb Co. Gilead Sciences Inc. Ironwood Johnson & Johnson Services Inc. Lilly Merck & Co. Inc. Pfizer Inc. Sanofi Takeda Pharmaceutical Co. Ltd. UCB For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Irritable Bowel Syndrome and Inflammatory Bowel Disease Therapeutics Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Medscape
30-07-2025
- Medscape
Patients With IBD and PSC Face Elevated CRC Risk
TOPLINE: Patients with inflammatory bowel disease (IBD), especially those who had been diagnosed before 20 years of age, and with primary sclerosing cholangitis (PSC) had an elevated risk for colorectal cancer (CRC). METHODOLOGY: Researchers conducted a cohort study to analyse the effect of IBD with and without PSC on the risk for CRC. They enrolled patients with IBD diagnosed between January 1969 and December 2014 from the Swedish National Patient Register, including those who underwent colectomy. Patients were classified as those having PSC on the basis of the diagnosis of cholangitis. A total of 85,813 patients with IBD alone and 3066 with IBD and concomitant PSC were included. Each patient with IBD was matched with five control individuals from the general population without IBD (n = 432,037). Information on the diagnosis of CRC and cause of death was obtained using register data. Synchronous cancer was defined as two or more CRCs occurring within or less than 180 days. TAKEAWAY: Patients with IBD and concomitant PSC and those without PSC had an increased risk for CRC (incidence rate [IR], 269 and 95 cases per 100,000 person-years, respectively) compared with matched control individuals (IR, 58 cases per 100,000 person-years; P < .001). Those with unclassified IBD and PSC had the highest risk for CRC (IR ratio [IRR], 7.38; 95% CI, 5.56-9.63). Compared with control individuals, patients diagnosed with IBD before the age of 20 years, with or without PSC, demonstrated a significantly elevated risk for CRC (IRR, 74.97 and 18.75, respectively; P < .001). CRC was more likely to be in the proximal colon among patients with IBD and PSC than among those with IBD without PSC and control individuals, with 37.5% vs 27% and 22.4% of CRC being located in the caecum and ascending colon. Synchronous cancers were found in 4.7% of patients with IBD and PSC and 4.4% of those with IBD without PSC vs 1.9% of control individuals (P < .001). Those with IBD and PSC had the highest mortality (adjusted hazard ratio, 2.56; P < .001). IN PRACTICE: "In PSC+ [IBD with a concomitant PSC diagnosis], primary CRC is more often located in the proximal colon. This must be considered when counselling patients with IBD regarding type of resection for cancer and choice of restorative surgery," the authors of the study wrote. SOURCE: This study was led by Maie Abdalla, MD, PhD, Department of Surgery and Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden. It was published online on July 22, 2025, in Clinical Gastroenterology and Hepatology. LIMITATIONS: The register included only hospital discharge diagnoses before 2001, potentially missing outpatients with milder disease. Variables such as diet, smoking, family history of CRC, colitis severity, tumour stage, and others could not be accounted for. PSC lacks a specific International Classification of Diseases code; therefore, researchers had to combine a cholangitis code with an IBD diagnosis to identify cases. DISCLOSURES: This study was supported by the Medical Research Council of Southeast Sweden and by grants from the Swedish state under the agreement between the Swedish government and the county councils, the ALF agreement, Sweden. One author reported being an employee of AstraZeneca and having shares in the same. The author also reported receiving prior research funding and honoraria for lectures and consultancy from various pharmaceutical companies. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
